



Combigan® (brimonidine/timolol) – First-time authorized brand alternative

- On January 19, 2022, [Apotex launched](#) an authorized brand alternative of Allergan's [Combigan \(brimonidine/timolol\)](#) ophthalmic solution.
- Combigan is approved for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.